Docetaxel–trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

References

• McGroganBTGilmartinBCarneyDNMcCannATaxanes, micro-tubules and chemoresistant breast cancerBiochim Biophys Acta2008178529613218068131
   PubMed Web of Science ®Google Scholar
• BraakhuisBJHillBTDietelMIn vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cellsAnticancer Res1994141A2052087909419
   PubMed Web of Science ®Google Scholar
• JonesSEErbanJOvermoyerBRandomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancerJ Clin Oncol200523245542555116110015
   PubMed Web of Science ®Google Scholar
• DenmanJPGilbarPJAbdiEAHypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxelJ Clin Oncol200220112760276112039945
   PubMed Web of Science ®Google Scholar
• ImmordinoMLBrusaPArpiccoSStellaBDosioFCattelLPreparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxelJ Control Release200391341742912932719
   PubMed Web of Science ®Google Scholar
• StraubingerRMBalasubramanianSVPreparation and characterization of taxane-containing liposomesMethods in Enzymology20053919711715721376
   PubMed Web of Science ®Google Scholar
• PereiraSEgbuRJannatiGAl-JamalWTDocetaxel-loaded liposomes: the effect of lipid composition and purification on drug encapsulation and in vitro toxicityInt J Pharm2016514115015927863659
   PubMed Web of Science ®Google Scholar
• YoshizawaYKonoYOgawaraKKimuraTHigakiKPEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacyInt J Pharm20114121–213214121507344
   PubMed Web of Science ®Google Scholar
• SuWZhangSLiCHaoXZhangJEfficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancerZhonghua Zhong Liu Za Zhi2015375379382 Chinese [with English abstract]26463031
   PubMedGoogle Scholar
• WangHYZhangXRComparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancerZhongguo Yi Xue Ke Xue Yuan Xue Bao201436330530824997825
   PubMedGoogle Scholar
• DeekenJFSlackRWeissGJA phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignanciesCancer Chemother Pharmacol201371362763323274395
   PubMed Web of Science ®Google Scholar
• ChenYChenJChengYA lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluationJ Liposome Res2017271647327031365
   PubMed Web of Science ®Google Scholar
• XuYMengHPaclitaxel-loaded stealth liposomes: development, characterization, pharmacokinetics, and biodistributionArtif Cells Nanomed Biotechnol201644135035525162671
   PubMed Web of Science ®Google Scholar
• WangXZhouJWangYA phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusionsEur J Cancer20104681474148020207133
   PubMed Web of Science ®Google Scholar
• LiJGuoCFengFCo-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacySci Rep201663878727934917
   PubMed Web of Science ®Google Scholar
• EloyJOPetrilliRTopanJFCo-loaded paclitaxel/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapyColloids Surf B Biointerfaces2016141748226836480
   PubMed Web of Science ®Google Scholar
• QuMHZengRFFangSDaiQSLiHPLongJTLiposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancerInt J Pharm20144741–211212225138252
   PubMedGoogle Scholar
• ChangMLuSZhangFRGD-modified pH-sensitive liposomes for docetaxel tumor targetingColloids Surf B Biointerfaces201512917518225851582
   PubMed Web of Science ®Google Scholar
• RanjanABenjaminCJNegussieAHBiodistribution and efficacy of low temperature-sensitive liposome encapsulated docetaxel combined with mild hyperthermia in a mouse model of prostate cancerPharm Res201633102459246927343000
   PubMed Web of Science ®Google Scholar
• LiangZYangNJiangYTargeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancerInt J Pharm2015494133734526299762
   PubMedGoogle Scholar
• LiXZhangJWangDKPanWSAnti-tumor activity of folate receptor targeting docetaxel-loaded membrane-modified liposomesYao Xue Xue Bao201348711421147 Chinese [with English abstract]24133983
   PubMedGoogle Scholar
• TongLChenWWuJLi H. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cellsAnticancer Drugs201425324425424275314
   PubMed Web of Science ®Google Scholar
• ChenLLiuYWangWLiuKEffect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapyOncol Lett2015101778426170980
   PubMed Web of Science ®Google Scholar
• YuanMQZhuFLouJYThe anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancerDrug Res (Stuttg)201464419520224154938
   PubMedGoogle Scholar
• ZhaiGWuJYuBGuoCYangXLeeRJA transferrin receptor-targeted liposomal formulation for docetaxelJ Nanosci Nanotechnol20101085129513621125861
   PubMed Web of Science ®Google Scholar
• MamotCRitschardRWickiATolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation studyLancet Oncol201213121234124123153506
   PubMed Web of Science ®Google Scholar
• HynesNESternDFThe biology of erbB-2/neu/HER-2 and its role in cancerBiochim Biophys Acta199411982–31651847819273
   PubMed Web of Science ®Google Scholar
• LoRussoPKropIMillerKA phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancerCancer Res20157515 abstract CT234
   Google Scholar
• ADC Review. MM-302 Misses Endpoint in Phase II Hermione Trial2016 Available from: https://adcreview.com/news/mm-302-misses-endpoint-phase-ii-hermione-trial/Accessed July 27, 2017
   Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• MetroGMottoleseMFabiAHER-2-positive metastatic breast cancer: trastuzumab and beyondExpert Opin Pharmacother200892583260118803447
   PubMed Web of Science ®Google Scholar
• GaoJSunJLiHLyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencingBiomaterials20103192655266420035999
   PubMed Web of Science ®Google Scholar
• BanghamADStandishMMWatkinsJCDiffusion of univalent ions across the lamellae of swollen phospholipidsJ Mol Biol19651312382525859039
   PubMed Web of Science ®Google Scholar
• MaedaHThe enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdv Enzyme Regul20014118920711384745
   PubMedGoogle Scholar
• SawantRRTorchilinVPChallenges in development of targeted liposomal therapeuticsAAPS J201214230331522415612
   PubMed Web of Science ®Google Scholar
• Thermo scientific pierce crosslinking technical handbook.pdf.
   Google Scholar
• ChoiWILeeJHKimJYTargeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumabNanomedicine201511235936825262581
   PubMed Web of Science ®Google Scholar
• ZhouZBadkasAStevensonMLeeJYLeungYKHerceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug deliveryInt J Pharm20154871–2819025865568
   PubMed Web of Science ®Google Scholar
• ShariatSBadieeAJaafariMRMortazaviSAOptimization of a method to prepare liposomes containing HER2/Neu-derived peptide as a vaccine delivery system for breast cancerIran J Pharm Res201413Suppl152524711825
   PubMedGoogle Scholar
• SoemaPCWillemsGJJiskootWAmorijJPKerstenGFPredicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approachEur J Pharm Biopharm20159442743526144666
   PubMed Web of Science ®Google Scholar
• GargMBAcklandSPSimple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urineJ Chromatogr B Biomed Sci Appl2000748238338811087080
   PubMed Web of Science ®Google Scholar
• BradfordMMA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnal Biochem197672248254942051
   PubMed Web of Science ®Google Scholar
• HultinLEMatudJLGiorgiJVQuantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibratorCytometry19983321231329773872
   PubMedGoogle Scholar
• HurrellTOuthoffKThe in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinomaCancer Cell Int20131319724119761
   PubMedGoogle Scholar
• BregoliLMoviaDGavigan-ImedioJDLysaghtJReynoldsJPrina-MelloANanomedicine applied to translational oncology: a future perspective on cancer treatmentNanomedicine20161218110326370707
   PubMed Web of Science ®Google Scholar
• FanciullinoRMollardSCorreardFBiodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size mattersPharm Res201431102677268424752479
   PubMed Web of Science ®Google Scholar
• BitounisDFanciullinoRIliadisACiccoliniJOptimizing druggability through liposomal formulations: new approaches to an old conceptISRN Pharm2012201273843222474607
   PubMedGoogle Scholar
• SoniKSLeiFDesaleSSMarkyLACohenSMBronichTKTuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancerJ Control Release201726427628728870832
   PubMed Web of Science ®Google Scholar
• RajaSMDesaleSSMohapatraBMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionOncotarget201679105221053526859680
   PubMedGoogle Scholar